Cargando…

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation

BACKGROUND: The Intergroup Exemestane Study (IES) (ISRCTN11883920) demonstrated improved survival for postmenopausal women with ER-positive/unknown primary breast cancer who switched to exemestane after 2–3 years tamoxifen, compared with those continuing on tamoxifen to complete 5 years therapy. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fallowfield, L J, Kilburn, L S, Langridge, C, Snowdon, C F, Bliss, J M, Coombes, R C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304414/ https://www.ncbi.nlm.nih.gov/pubmed/22353807 http://dx.doi.org/10.1038/bjc.2012.43

Ejemplares similares

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen
por: Bertelli, G., et al.
Publicado: (2010)

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES
por: Cheang, M. C. U., et al.
Publicado: (2017)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women
por: Thomas, R, et al.
Publicado: (2008)

The attitudes of 1066 patients with cancer towards participation in randomised clinical trials
por: Jenkins, V, et al.
Publicado: (2010)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Long-term efficacy and safety of exemestane in the treatment of breast cancer
por: Walker, GA, et al.
Publicado: (2013)

The informational roles and psychological health of members of 10 oncology multidisciplinary teams in the UK
por: Catt, S, et al.
Publicado: (2005)

Distinguishing Intergroup and Long-Distance Relationships
por: Pisor, Anne C., et al.
Publicado: (2022)

Drivers and barriers to patient participation in RCTs
por: Jenkins, V, et al.
Publicado: (2013)

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
por: Blinman, Prunella, et al.
Publicado: (2016)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

How Can Intergroup Interaction Be Bad If Intergroup Contact Is Good? Exploring and Reconciling an Apparent Paradox in the Science of Intergroup Relations
por: MacInnis, Cara C., et al.
Publicado: (2015)

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
por: Barnadas, A, et al.
Publicado: (2009)

The evolution of intergroup cooperation
por: Rodrigues, António M. M., et al.
Publicado: (2023)

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer
por: Hertz, Daniel L., et al.
Publicado: (2016)

Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase?
por: Leonard, R, et al.
Publicado: (2011)

Benefit finding and post-traumatic growth in long-term colorectal cancer survivors: prevalence, determinants, and associations with quality of life
por: Jansen, L, et al.
Publicado: (2011)

Subepithelial Corneal Deposits Associated with Exemestane
por: Amireskandari, Annahita, et al.
Publicado: (2020)

Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates
por: Teslenko, Irina, et al.
Publicado: (2022)

The challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective
por: Kilburn, Lucy S, et al.
Publicado: (2014)

Long-term effect of a nurse-led psychosocial intervention on health-related quality of life in patients with head and neck cancer: a randomised controlled trial
por: van der Meulen, I C, et al.
Publicado: (2014)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

Impact of sentinel node biopsy on long-term quality of life in breast cancer patients
por: De Gournay, E, et al.
Publicado: (2013)

Intergroup contact in multiple adolescents’ contexts: The Intergroup Contact Interactions Scale (ICIS)
por: Karataş, Savaş, et al.
Publicado: (2023)

Role of the UGT2B17 deletion in exemestane pharmacogenetics
por: Luo, Shaman, et al.
Publicado: (2017)

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
por: Zilembo, N., et al.
Publicado: (1995)

Exemestane in early breast cancer: a review
por: Untch, Michael, et al.
Publicado: (2008)

Antiproliferative effect of exemestane in lung cancer cells
por: Koutras, Angelos, et al.
Publicado: (2009)

Clinical utility of exemestane in the treatment of breast cancer
por: Zucchini, Giorgia, et al.
Publicado: (2015)

Bone marrow micrometastases in early breast cancer–30-year outcome
por: Mansi, J, et al.
Publicado: (2016)

(Bad) Feelings about Meeting Them? Episodic and Chronic Intergroup Emotions Associated with Positive and Negative Intergroup Contact As Predictors of Intergroup Behavior
por: Kauff, Mathias, et al.
Publicado: (2017)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Intergroup relationships and quality improvement in healthcare
por: Bartunek, Jean M
Publicado: (2011)

A Network Analysis of the Association Between Intergroup Contact and Intergroup Relations
por: Yu, Dongfang, et al.
Publicado: (2022)

Why intergroup variation matters for understanding behaviour
por: Kaufhold, Stephan P., et al.
Publicado: (2019)

Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome
por: Macdonald, L, et al.
Publicado: (2005)

Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane
por: Luo, Shaman, et al.
Publicado: (2018)

Quality of life, long-term survivors and long-term outcome from the ABC-02 study
por: Bridgewater, John, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5b0j924hqej7jkvph42efgkj0b